Lupin, one of the leading pharmaceutical companies in India, will be announcing its second quarter financial results on Monday, Oct. 27, 2014.

Angel Broking is of the opinion that  the company is expected to post a net sales Rs 33.60 billion V/s Rs 26.31 billion, a yoy growth of 27.7%. The sales growth would be driven by both exports and domestic.

On the operating front, the gross margin is expected to come in flat at 68.0%; consequently taking the operating margins to 24.3% V/s 23.7% in 2QFY2014. Consequently, the net profit is expected to come in at Rs 5.31 billion V/s Rs 4.06 billion in 2QFY2014; a yoy growth of 30.8%. We maintain our neutral rating on the stock, it said.

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.